# Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes

> **NIH NIH R01** · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2022 · $729,791

## Abstract

Project Summary
This project utilizes translational approaches to use novel assays to understand the emergence of resistance to
drugs to treat Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). Drug-resistant TB
incidence has increased 80% worldwide over the past 15 years with high mortality, prolonged treatment course,
and poor outcomes. Global multi-drug resistant TB (MDR-TB) cure rates average 65% and as many as 11% of
MDR-TB patients develop amplification of drug-resistance on treatment. While emergent drug-resistance is a
major challenge it is often detected too late. This application will study pairs of Mtb strains from patients that had
drug-susceptible TB at baseline then developed drug-resistant TB. There is extensive clinical and adherence
data for these patients. Functional assays for drug-resistance mechanisms will be done to better understand
development of drug-resistance under treatment.

## Key facts

- **NIH application ID:** 10403937
- **Project number:** 5R01AI114900-08
- **Recipient organization:** ALBERT EINSTEIN COLLEGE OF MEDICINE
- **Principal Investigator:** Michelle H Larsen
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $729,791
- **Award type:** 5
- **Project period:** 2015-05-01 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10403937

## Citation

> US National Institutes of Health, RePORTER application 10403937, Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes (5R01AI114900-08). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10403937. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*